Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 10, Issue 10, Pages 1165-1176Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERI.12.110
Keywords
carbapenemases; CTX-M-beta-lactamases; ExPEC; extraintestinal pathogenic Escherichia coli; KPC; laboratory detection; NDM; OXA-48; plasmid-mediated AmpC beta-lactamases; treatment options
Funding
- Merck
- Astra Zeneca
Ask authors/readers for more resources
Expert Rev. Anti Infect Ther. 10(10), 1165-1176 (2012) Escherichia coli remains one of the most frequent causes of nosocomial and community-acquired bacterial infections including urinary tract infections, enteric infections and systemic infections in humans. Extraintestinal pathogenic E. coli (ExPEC) had emerged during the 2000s as an important player in the resistance to antibiotics, especially to the cephalosporins and fluoroquinolones. Most importantly, among ExPEC is the increasing recognition of isolates producing 'newer beta-lactamases' that consist of plasmid-mediated AmpC beta-lactamases (e.g., CMY), extended-spectrum beta-lactannases (e.g., CTX-M) and carbapenemases (e.g., New Delhi metallo-beta-lactamase, Klebsiella pneumonaie carbapenemase and OXA-48). This review will highlight recent aspects on antimicrobial resistance in ExPEC, including the laboratory detection of these isolates, and describe some treatment options for infections due to antimicrobial-resistant isolates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available